 |
|
Breast Cancer Prevention: Time for Randomized Controlled Trials With Statins
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Eliassen et al1 conclude from their epidemiological study that the beneficial effects of statins seen in the laboratory may not be applicable to humans. However, the epidemiological evidence for statin effects in breast cancer has been mixed, although heavily weighted toward no effect. In their study, 74 904 women were screened and 3177 invasive breast cancer cases occurred.1 Of these women, 237 had used statins, but only 127 had used statins for longer than 2 years. Furthermore, only 21 women had used statins in the important group of estrogen receptror– and progesterone receptor–negative invasive cancers, and of these women, only 13 had used statins longer than 2 years. Hormone receptor–negative cancers have a worse prognosis, and some data suggest that statins may help prevent hormone receptor–negative breast cancer.2
The authors point out that in experimental models, replacement of estrogen negates the effects of statins on cell cycle progression,3 yet more than . . . [Full Text of this Article]
AUTHOR INFORMATION
Julian Sprague, MD;
Marie Wood, MD
RELATED ARTICLES
Breast Cancer Prevention: Time for Randomized Controlled Trials With Statins—Reply
A. Heather Eliassen and Susan E. Hankinson
Arch Intern Med. 2006;166(10):1144.
EXTRACT
| FULL TEXT
Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer
A. Heather Eliassen, Graham A. Colditz, Bernard Rosner, Walter C. Willett, and Susan E. Hankinson
Arch Intern Med. 2005;165(19):2264-2271.
ABSTRACT
| FULL TEXT
|
